Dr Michelle O’Donoghue, Brigham and Women’s Hospital, Boston, USA, discusses the results of the Phase 2 OCEAN(a) DOSE study of the siRNA, olpasiran, in patients with cardiovascular disease and elevated Lp(a), and the absolute Lp(a) reductions that are likely to be needed for beneficial effects on clinical outcomes.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.